Segment Information

9 Months Ended

Mar. 28, 2015

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT INFORMATION

The Company has five reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences, along with an Other category. In conjunction with the Elan acquisition on December 18, 2013, the Company expanded its operating segments to include the Specialty Sciences segment, which is comprised of assets focused on the treatment of Multiple Sclerosis (Tysabri^®). The majority of corporate expenses, which generally represent shared services, are charged to operating segments as part of a corporate allocation. Unallocated expenses relate to certain corporate services not allocated to the segments.

The below tables show select financial measures by reporting segment (in millions):

	Three Months Ended							Balance at March 28, 2015
	March 28, 2015
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
Consumer Healthcare	$	537.3	$	91.8		$	8.6	$	6,143.3
Nutritionals	129.9		11.2			7.2		1,037.8
Rx Pharmaceuticals	251.6		100.0			18.3		2,605.9
API	30.7		10.5			0.5		252.2
Specialty Sciences	81.9		5.5			72.8		6,055.8
Other	17.7		1.3			0.4		87.8
Unallocated expenses	—		(21.1		)	—		—
Total	$	1,049.1	$	199.2		$	107.8	$	16,182.8

	Three Months Ended (1)							Balance at March 29, 2014
	March 29, 2014
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
Consumer Healthcare	$	537.3	$	84.4		$	5.3	$	2,555.2
Nutritionals	137.8		7.3			7.3		1,011.5
Rx Pharmaceuticals	223.4		77.0			17.5		1,985.4
API	32.0		6.8			0.5		286.8
Specialty Sciences	53.4		(54.5		)	76.4		7,799.5
Other	20.2		0.8			0.4		104.4
Unallocated expenses	—		(18.5		)	—		—
Total	$	1,004.2	$	103.3		$	107.4	$	13,742.8

	Nine Months Ended
	March 28, 2015
	Net Sales		Operating Income (Loss)			Amortization of Intangibles
Consumer Healthcare	$	1,560.2	$	232.0		$	26.0
Nutritionals	385.7		26.9			21.6
Rx Pharmaceuticals	722.8		274.4			53.3
API	85.5		24.9			1.5
Specialty Sciences	260.4		29.8			218.4
Other	57.7		3.4			1.1
Unallocated expenses	—		(70.7		)	—
Total	$	3,072.3	$	520.7		$	321.9

	Nine Months Ended (1)
	March 29, 2014
	Net Sales		Operating Income (Loss)			Amortization of Intangibles
Consumer Healthcare	$	1,612.1	$	263.8		$	15.9
Nutritionals	406.6		28.3			22.1
Rx Pharmaceuticals	673.6		260.5			55.2
API	105.2		37.4			1.6
Specialty Sciences (2)	60.8		(73.5		)	85.0
Other	58.3		2.6			1.3
Unallocated expenses	—		(149.7		)	—
Total	$	2,916.6	$	369.5		$	181.1

⁽¹⁾Amounts may not foot due to rounding.

⁽²⁾Specialty Sciences represents activity for the period beginning on December 18, 2013 and ending March 29, 2014.

In conjunction with the closing of the Omega acquisition on March 30, 2015, the Company changed its reporting segments to better align with the Company's organizational structure and reflect the way in which the Chief Operating Decision Maker now reviews the Company's operating results. This reporting change will take effect starting in the fourth quarter of fiscal 2015. See Note 1 for more information.